Fresenius and WuXi Biologics will work together to develop up to 37 biosimilar candidates targeting a range of therapeutic areas, giving the German company ample scope to bolster ...

Anthropic hopes Powerful AI will “match or exceed the cognitive capabilities of top human experts across scientific disciplines”.

Xtandi's label as the cancer treatment paradigm shifts towards the use of mutation-specific targeted therapies.

Reaction from the life sciences industry to the Autumn Budget was mixed, with the government opting for a more macro focus on business scaling.

Pathos AI has secured $237m in a Series E round to expand its clinical oncology pipeline and scale its AI drug development platform.

Formation Bio has launched the Formation Bio Drug Development Accelerator Fund to broaden the company's clinical-stage medicines portfolio.

Enthorin has signed an option-to-license deal with Rumi to advance ENT-7340 for FXS, as well as other intellectual and developmental disabilities.

Gilead plans to develop HCXT-2001 both as a monotherapy and in combination with its own IBD hopeful, emvistegrast.

Gaelic Labs is eyeing competitive benefits from its 2025 acquisition of fellow Irish beta-lactams manufacturer and further expansion.